The mission of NNECOS is to promote the highest quality care for patients with cancer and blood disorders in our region through professional networking, education, and scientific research, as well as patient advocacy and public policy.
March 22 - FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
March 19 - FDA grants accelerated approval to ponatinib with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
March 7 - FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma
March 6 - FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma
March 6 -FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia
March 1 - FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
February 16 - FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer | FDA
February 16 - FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma | FDA
February 15 - FDA approves tepotinib for metastatic non-small cell lung cancer
February 13 - FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma
January 19 - FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma
January 12 - FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer
December 15 - FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer
December 14 - FDA approves belzutifan for advanced renal cell carcinoma
December 13 - FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma
December 1 -FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma
August - FDA approves new indication for anemia without previous erythropoiesis stimulating agent use (ESAnaïve) in adult patients with very low-to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions
Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection: